Medical Communications in an Agency Setting: A Career Option for Pharmacists

2021 ◽  
pp. 089719002098713
Author(s):  
Samantha Miernicki ◽  
Gregory Anagnostos ◽  
Joseph P. Nathan ◽  
Sara Grossman
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry ◽  
Opinion Leaders ◽  
Brand Identification ◽  
Advisory Boards ◽  
Career Option ◽  
Key Characteristics ◽  
Key Opinion Leaders ◽  
Video Presentations

Medical communications (MedComms) agencies serve the varied needs of the pharmaceutical industry and other healthcare-related organizations. These agencies present a unique practice opportunity for pharmacists who possess the requisite knowledge and skillset to flourish and grow professionally in this environment. Published information about this sector of the industry is limited. To this end, this article provides an overview of the MedComms agency setting and describes the services provided by such agencies. These include the development of branded and/or unbranded communications materials in the form of publications, oral and video presentations, slide decks, and other materials. MedComms professionals also facilitate and support professional meetings and presentations, such as congresses, symposia, and advisory boards. Other services that MedComms agencies provide include engaging key opinion leaders, providing clinical trial services, and brand identification or positioning. The article describes the opportunities for pharmacists in this field, key characteristics and skills needed to succeed in this industry, and the pathway for pharmacists to enter this field.

scholarly journals Key opinion leaders’ guide to spinning a disappointing clinical trial result

BMJ ◽  
2018 ◽  
pp. k5207
Author(s):  
Adam Hartley ◽  
Mit Shah ◽  
Alexandra N Nowbar ◽  
Christopher Rajkumar ◽  
James P Howard ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Trial Result ◽  
Opinion Leaders ◽  
Clinical Trial Result ◽  
Key Opinion Leaders

KOLs

2021 ◽  
pp. 139-162
Author(s):  
Edward Shorter
Keyword(s):  
Pharmaceutical Industry ◽  
Marketing Strategies ◽  
Opinion Leaders ◽  
True Nature ◽  
Key Opinion Leaders ◽  
Effective Compound

This chapter considers the physicians who advised the pharmaceutical industry in the interest of bringing an effective compound to the attention of the profession. It mentions Roland Kuhn, the Swiss asylum psychiatrist who in 1957 discovered the effectiveness of imipramine in depression and advised about marketing strategies to use to sell the drug. It also highlights the true nature of the testimonials of physicians, which is well known to the industry. The industry’s contempt for them is shown by its vernacular term for sources, which are called “stables.” The chapter focuses on the “stables” of the 1980s that later became Key Opinion Leaders (KOLs). It points out that the sardonic term KOL first appeared in industry correspondence as an insider expression for academics.

Corporate Disguises in Medical Science

2011 ◽  
Vol 31 (6) ◽  
pp. 482-492 ◽  
Author(s):  
Sergio Sismondo
Keyword(s):  
Medical Education ◽  
Pharmaceutical Industry ◽  
Medical Research ◽  
Continuing Medical Education ◽  
Medical Science ◽  
Opinion Leaders ◽  
Key Opinion Leaders ◽  
Research And Education ◽  
Approved Drugs ◽  
Education Courses

Roughly 40% of the sizeable medical research and literature on recently approved drugs is “ghost managed” by the pharmaceutical industry and its agents. Research is performed and articles are written by companies and their agents, though apparently independent academics serve as authors on the publications. Similarly, the industry hires academic scientists, termed key opinion leaders, to serve as its speakers and to deliver its continuing medical education courses. In the ghost management of knowledge, and its dissemination through key opinion leaders, we see the pharmaceutical industry attempting to hide or disguise the interests behind its research and education.

Cooperation in R&D in the pharmaceutical industry: Technological and clinical trial networks in oncology

2022 ◽  
Vol 176 ◽  
pp. 121426
Author(s):  
Giovana Maria Lanchoti Fiori ◽  
Fernanda Gisele Basso ◽  
Geciane Silveira Porto
Keyword(s):  
Clinical Trial ◽  
Pharmaceutical Industry

Identifying Key Opinion Leaders in Social Media via Modality-Consistent Harmonized Discriminant Embedding

2020 ◽  
Vol 50 (2) ◽  
pp. 717-728 ◽  
Author(s):  
Yang Liu ◽  
Zhonglei Gu ◽  
Tobey H. Ko ◽  
Jiming Liu
Keyword(s):  
Social Media ◽  
Opinion Leaders ◽  
Key Opinion Leaders

scholarly journals Should the drug industry work with key opinion leaders? No

BMJ ◽  
2008 ◽  
Vol 336 (7658) ◽  
pp. 1405-1405 ◽  
Author(s):  
Giovanni A Fava
Keyword(s):  
Opinion Leaders ◽  
Drug Industry ◽  
Key Opinion Leaders

Editor's Memo

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
Robert Figlin
Keyword(s):  
Cancer Research ◽  
Health Equity ◽  
Cancer Care ◽  
Scientific Collaboration ◽  
Opinion Leaders ◽  
High Quality ◽  
Quality Cancer Care ◽  
Key Opinion Leaders ◽  
American Society ◽  
Silver Lining

The COVID-19 pandemic has exposed fundamental disparities in the provision of health care across our nation and exacerbated the differences in health outcomes associated with race, socioeconomic and other demographic factors. A silver lining however is that pandemic precarity has inspired tremendous scientific collaboration among clinicians, researchers, and key opinion leaders. In this line, this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO21) which was kicked off virtually on June 4 through June 8, not only celebrated latest breakthroughs in cancer research, treatment and patient care, but also focused on health equity in cancer care. ASCO21’s fitting theme - Health equity “doing right by the patients for whom we care” reflected addressing complex forces and systems that have created disparities in cancer care, treatment, and research and identifying ways to ensure that all patients have access to and benefit from the latest cancer advances and high-quality cancer care.

Overdiagnosis and Overtreatment

2020 ◽  
pp. 41-52
Author(s):  
Joel Paris
Keyword(s):  
Pharmaceutical Industry ◽  
Mental Disorders ◽  
Antidepressant Drugs ◽  
Psychiatric Epidemiology ◽  
Opinion Leaders ◽  
Main Form

Psychiatry has embraced overdiagnosis both because it does not understand the causes of mental disorders and because clinicians are keen to use the tools they already have for treatment. These trends have most notable effects on the overprescription of antidepressant drugs. Overdiagnosis has also infiltrated psychiatric epidemiology, since most studies are DSM-based. All these factors have supported diagnostic epidemics, in which identification of certain categories increases dramatically over relatively brief periods of time. When drugs are believed to be the main form of treatment, these trends have been further encouraged by the pharmaceutical industry, and by opinion leaders who are sponsored by Big Pharma.

Sign in / Sign up

Export Citation Format

Share Document